Quantcast

NW Bio expands cancer drug study

Northwest Biotherapeutics Inc., of Bethesda, which is developing non-toxic personalized immune therapies for solid tumor cancers, said it completed recruiting patients for the first phase of a clinical trial testing the efficacy of a potential cancer drug.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

 

[index]
[index]
[i]
[i]
[id, count]
[id, count]
[f.tagName.toLowerCase()]
[f.tagName.toLowerCase()]
[id, validationType, arg1, arg2]
[id, validationType, arg1, arg2]
[field.tagName.toLowerCase()]
[field.tagName.toLowerCase()]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]